A phase I study of suramin with once- or twice-monthly dosing in patients with advanced cancer

Cancer Chemotherapy and Pharmacology

Volumn 50, Issue 1, 2002, Pages 1-5

  Ryan, Christopher W ^a   Vokes, Everett E ^a   Vogelzang, Nicholas J ^a   Janisch, Linda ^a   Kobayashi, Ken ^a   Ratain, Mark J ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Adaptive control; Clinical trial; Phase I; Suramin

Indexed keywords

SURAMIN;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COLITIS; DOSE CALCULATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG TOLERABILITY; DRUG TOLERANCE; FATIGUE; FEMALE; FEVER; FOLLOW UP; HUMAN; LUNG CARCINOMA; MALE; PAIN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CARCINOMA; SOLID TUMOR; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BIOLOGICAL AVAILABILITY; DRUG MONITORING; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; SAFETY; SURAMIN;

EID: 0036305931     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-002-0458-y     Document Type: Article

References (8)

1. Suramin: Development of a population pharmacokinetic model and its use with intermittent short infusions to control plasma drug concentration in patients with prostate cancer
2. Phase I study of suramin given by intermittent infusion without adaptive control in patients with advanced cancer
3. Suramin-induced polyneuropathy
4. EIect of suramin on human prostate cancer cells in vitro
5. Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: Results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone
6. Evaluation of neuropathy in patients on suramin treatment
7. A rapid HPLC assay for suramin in plasma
8. A phase III trial of 3 different doses of suramin (SUR) in metastatic hormone refractory prostate cancer (HRPC): Safety profile of CALGB 9480